ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Higher eGFR at Dialysis Initiation Tied to Lower Survival in Children
July 22, 2019Higher eGFR at Dialysis Initiation Tied to Lower Survival in Children. -
Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology
February 20, 2019Japan-based Taiho Pharmaceutical has signed an agreement to licence its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor candidate TAS6417 for lung cancer to Cullinan Oncology.... -
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
September 28, 2018Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth fact -
Tarloxitinib puts tumour-seeking tail on anti-EGFR drug to target lung cancer
October 26, 2017Researchers have proposed a unique way to reach the concentration of anti-EGFR drug needed to fight exon 20 insertions without harming healthy tissues… -
AstraZeneca lung cancer drug proves able to shrink EGFR mutation-positive tumours
October 18, 2017AstraZeneca and its partner and Chinese medicine (also known as Chi-Med) have announced positive data on savolitinib combined with AstraZeneca's Tagrisso or Iressa
Pharma Sources Insight January 2025
